2 active not recruiting. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 2 |
Follow RCC: new trials by email Literature Review of RCC trials Research Report on RCC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) Belzutifan - Advanced Solid Tumors, Solid Tumor | Phase 1 | Active not recruiting | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 120 | 2016-12-07 | 2026-10-26 |
| A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) MK-3795, Nivolumab, Cabozantinib - ccRCC, RCC | Phase 1 | Active not recruiting | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 110 | 2014-11-25 | 2024-06-17 |
Carcinoma, Renal Cell (2) · Kidney Neoplasms (2) · Glioblastoma (1) · Neoplasm Metastasis (1)
Adenocarcinoma (2) · Carcinoma (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Kidney Diseases (2) · Male Urogenital Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Urologic Diseases (2) · Urologic Neoplasms (2) · Astrocytoma (1)
belzutifan (2) · Nivolumab (1) · PT2385 (1) · cabozantinib (1) · endothelial PAS domain-containing protein 1 (1)
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2)
United States (1)